BuyMeWhiskeyStock analysisAnswersBMY news
Home › Stock analysis › BMY

Bristol Myers Squibb (BMY) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET

Updated Oct 15, 2026, 4:00 PM ET

What changed since yesterday

BMY rises 2.2% to $60.57. Closed at $60.57, +2.18% vs the prior close of $59.28. Day range $60.39–$62.25, opened at $60.67.

Last close$60.57+2.18%
Day range60.39–62.25
Open60.67
Volume13.75M
52-week range42.52–68.64
Avg volume (20d)14.83M

BMY daily analysis — what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 15, 2026 — BMY rises 2.2% to $60.57
Oct 14, 2026 — BMY jumps 4.6% to $59.28
Oct 13, 2026 — BMY dips 1.6% to $56.67, a 3-month low, 4 down days in a row
Oct 12, 2026 — BMY dips 2.6% to $57.58, a 1-month low on 2.0x normal volume
Oct 9, 2026 — BMY dips 0.8% to $59.12
Oct 8, 2026 — BMY ends flat (-0.2%) to $59.58
Oct 7, 2026 — BMY ends flat (+0.2%) to $59.70
Oct 6, 2026 — BMY rises 1.3% to $59.59
Oct 5, 2026 — BMY slides 3.8% to $58.81, a 1-month low, 5 down days in a row
Oct 2, 2026 — BMY dips 0.5% to $61.15, 4 down days in a row

BMY latest news & SEC filings

Every SEC filing by or about BMY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Oct 5, 2026 · 4 — Insider trade report (Form 4)

Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings

Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.

Source: SEC EDGAR filing 0001995058-26-000007

Oct 2, 2026 · 4 — Insider trade report (Form 4)

Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001269070-26-000011

Oct 2, 2026 · 4 — Insider trade report (Form 4)

Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001688276-26-000010

Oct 2, 2026 · 4 — Insider trade report (Form 4)

Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001359067-26-000012

Oct 2, 2026 · 4 — Insider trade report (Form 4)

Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001418949-26-000010

Oct 2, 2026 · 4 — Insider trade report (Form 4)

Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001323134-26-000024

Aug 7, 2026 · SCHEDULE 13G — Passive stake (13G)

Passive stake (13G) — an investor reported owning more than 5%

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0000093751-26-000422

Jul 30, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)

Quarterly report (unaudited financial statements for the quarter)

Quarter ended Jun 30, 2026:

Source: SEC EDGAR filing 0000014272-26-000020

Jul 30, 2026 · 8-K — Current report

Current report — a filing companies must make within 4 business days of a major event

This is a results-day filing: the earnings press release is attached as an exhibit.

Source: SEC EDGAR filing 0000014272-26-000018

Things to know before you trade BMY

BMY market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 15, 202660.6762.2560.3960.5713.75M
Oct 14, 202656.8159.3956.5859.2814.05M
Oct 13, 202657.7858.0256.1556.6716.96M
Oct 12, 202660.1160.6856.7257.5822.56M
Oct 9, 202658.8859.7958.7459.129.25M
Oct 8, 202659.1059.9458.7359.5813.07M
Oct 7, 202659.4560.1059.0159.7011.09M
Oct 6, 202658.9459.6058.6459.599.89M
Oct 5, 202659.8960.1558.3358.8119.24M
Oct 2, 202660.6661.2460.2461.159.93M
Oct 1, 202662.2062.6161.2561.4610.77M
Sep 30, 202663.2864.1362.4062.4015.87M
Sep 29, 202663.5863.8961.9562.8615.84M
Sep 28, 202662.7763.9362.3063.8814.02M
Sep 25, 202661.7562.9161.4062.8610.67M
Sep 24, 202661.4061.5960.6061.5014.90M
Sep 23, 202662.3162.6561.0861.1515.84M
Sep 22, 202662.7363.0862.0362.2515.24M
Sep 21, 202663.0963.4062.6262.626.84M
Sep 18, 202662.7163.0762.1963.0636.85M

About Bristol Myers Squibb

Bristol Myers Squibb (BMY) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PRINCETON, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 14272.

BMY board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Peter J ArduiniDirectorJul 2, 2026
Christopher S. BoernerChief Executive OfficerMar 12, 2026
Deepak BhattDirectorFeb 3, 2026
Julia A HallerDirectorJun 16, 2026
Medina Manuel HidalgoDirectorFeb 3, 2026
Michael R. McmullenDirectorJul 2, 2026
Paula A PriceDirectorFeb 3, 2026
Derica W RiceDirectorJul 2, 2026
Theodore R. Ii SamuelsDirectorJul 2, 2026
Karen H VousdenDirectorFeb 3, 2026
Phyllis R YaleDirectorJul 2, 2026

Executive officers

NameTitleLatest filing
Christopher S. BoernerChief Executive OfficerMar 12, 2026
David V ElkinsEVP, Chief Financial OfficerApr 2, 2026
Cari GallmanEVP, General CounselAug 4, 2026
Benjamin HickeyPresident, RayzeBio Org.Mar 12, 2026
Lynelle HochPresident, Cell Therapy Org.Mar 12, 2026
Phil M HolzerSVP and ControllerAug 26, 2026
Adam LenkowskyEVP, Chief Commercial OfficerMay 5, 2026
Cristian MassacesiEVP,Chief Med Offr,Head of DevSep 10, 2026
Gregory Scott MeyersEVP, Chief Digital & Tech Off.Mar 12, 2026
Robert M PlengeEVP, Chief Research OfficerMar 12, 2026
Ahn Amanda PooleEVP, Chief People OfficerMar 12, 2026
Karin ShanahanEVP, Chief Supply Chain & OpsApr 2, 2026
Hiroshi Chris ShibutaniEVP, Chief Strategy OfficerMar 12, 2026
Bartie Wendy ShortEVP, Corporate AffairsSep 3, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
Sep 9, 2026Cristian MassacesiSale6,249$64.57
Aug 25, 2026Phil M HolzerSale500$67.50
Apr 1, 2026David V ElkinsSale25,519$61.60
Apr 1, 2026David V ElkinsSale4,481$62.05

BMY financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
Dec 31, 2025$48.19B$7.05B3.46$14.16B
Dec 31, 2024$48.30B$-8.95B-4.41$15.19B
Dec 31, 2023$45.01B$8.03B3.86$13.86B
Dec 31, 2022$46.16B$6.33B2.95$13.07B
Dec 31, 2021$46.38B$6.99B3.12$16.21B

Latest balance sheet: total assets $87.63B, total liabilities $65.31B, cash $8.72B (as of Jun 30, 2026).

BMY earnings / results-day log

DateFilingClose that day
Jul 30, 20268-K Item 2.02 (results)$64.86
Apr 30, 20268-K Item 2.02 (results)$60.59
Feb 5, 20268-K Item 2.02 (results)$59.52
Oct 30, 20258-K Item 2.02 (results)$45.62
Jul 31, 20258-K Item 2.02 (results)$43.31
Apr 24, 20258-K Item 2.02 (results)$48.69
Feb 6, 20258-K Item 2.02 (results)$57.42
Oct 31, 20248-K Item 2.02 (results)$55.77
Jul 26, 20248-K Item 2.02 (results)—
Apr 25, 20248-K Item 2.02 (results)—
Feb 2, 20248-K Item 2.02 (results)—
Oct 26, 20238-K Item 2.02 (results)—

Related stocks · Pharmaceutical Preparations

Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)

Popular today

Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)

More on BMY

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.